Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H.sub.2N—CH(R.sub.1)—CH.sub.2S—S—CH.sub.2—CH(R.sub.2—CONH—CH(R.sub.3)—COOR.sub.4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H.sub.2N—CH(R.sub.1)—CH.sub.2S—S—CH.sub.2—CH(R.sub.2—CONH—CH(R.sub.3)—COOR.sub.4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.

The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.

The instant invention provides for inositol derivatives, analogs, methods of preparation and uses that inhibit oncogenic signaling pathways and genes. In particular, the compounds disclosed selectively inhibit one or two classes and or isoforms of PI3K. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting KRAS by administering the compound to a patient in need of treatment of cancer.

The instant invention provides for inositol derivatives, analogs, methods of preparation and uses that inhibit oncogenic signaling pathways and genes. In particular, the compounds disclosed selectively inhibit one or two classes and or isoforms of PI3K. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting KRAS by administering the compound to a patient in need of treatment of cancer.

The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.

The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.